Over five-year analysis of ustekinumab therapy for moderate to severe psoriasis in Korea = Over five-year analysis of ustekinumab therapy for moderate to severe psoriasis in Korea

다국어 초록 (Multilingual Abstract)

Background: Ustekinumab is a humanized monoclonal antibody that targets the interleukin (IL)-12 and IL-23. Although this drug is widely used, data on long-term efficacy and safety in Korean patients with psoriasis have been limited.
Objectives: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis.
Methods: A retrospective study of patients with moderate to severe psoriasis, who have been treated with ustekinumab for at least 5 years was conducted. All patients’ sex, age, body mass index (BMI), medical records, previous psoriasis therapy, Psoriasis Area and Severity Index (PASI) score and adverse event were evaluated.
Results: Twenty-five patients (median age 47.0) had been treated with ustekinumab for over 5 years. Among them, the mean duration of psoriasis was 19.12 ± 8.45 years. The treatment duration of ustekinumab was 285.12 ± 8.48 weeks. Baseline PASI was 17.52 ± 7.37. PASI 75 was achieved by 92% of patients at week 28 and 96% of patients maintained PASI 75 during 5-year follow up period. Further, 64% of patients reached PASI 90 at 28 weeks, and 48% of patients maintained PASI 90 for 5 years. No unexpected adverse events were reported other than herpes zoster, herpes simplex, and elevated liver enzyme.
Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate to severe psoriasis.